How many drugs treat Cerebrovascular disease?

Drug Landscape tracks 2 marketed treatments for Cerebrovascular disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cerebrovascular-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cerebrovascular disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cerebrovascular disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cerebrovascular disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Vasodil	TOLAZOLINE	Novartis	tolazoline	Alpha-2A adrenergic receptor		1948-01-01
Praxilene	naftidrofuryl oxalate	Merck Serono (originally Lipha)	5-HT2 receptor antagonist, Peripheral vasodilator	5-hydroxytryptamine receptor 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Cerebrovascular disease
Merck Serono (originally Lipha) · 1 drug in Cerebrovascular disease
Novartis · 1 drug in Cerebrovascular disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cerebrovascular disease:

Cite this brief

Drug Landscape (2026). Cerebrovascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cerebrovascular-disease. Accessed 2026-06-10.

Cerebrovascular disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing